Altavo GmbH, a med­ical tech­nol­ogy startup for AI-based voice reha­bil­i­ta­tion, suc­cess­fully closed a Series A2 financ­ing round on Jan­u­ary 12, 2026. A Euro­pean con­sor­tium led by Novalis Biotech and bm|t is invest­ing € 3 mil­lion in the devel­op­ment of Altavo’s inno­v­a­tive arti­fi­cial voice. 

Altavo’s arti­fi­cial voice is designed to give voice­less peo­ple their own nat­ural-sound­ing voice, for exam­ple after a laryn­gec­tomy or dur­ing arti­fi­cial res­pi­ra­tion. The “Silent Speech” tech­nol­ogy devel­oped for this pur­pose in col­lab­o­ra­tion with researchers at the Tech­ni­cal Uni­ver­sity of Dres­den is based on non-inva­sive radar sen­sors and the lat­est AI algorithms.

In addi­tion to the two lead investors Novalis Biotech (Ghent, Bel­gium) and bm|t beteili­gungs­man­age­ment thürin­gen, other investors in the cur­rent round include: TGFS Tech­nolo­giegrün­der­fonds Sach­sen, High-Tech Grün­der­fonds (HTGF), TUDAG TU Dres­den AG, Ost­werk GmbH and pri­vate indi­vid­ual investors.

The now com­pleted Series A2 will finance the fur­ther estab­lish­ment of the com­pany, clin­i­cal study work and the devel­op­ment of the series prod­uct. Altavo’s tech­nol­ogy has the poten­tial to improve the qual­ity of life of voice­less peo­ple and fun­da­men­tally opens up new pos­si­bil­i­ties in silent inter­ac­tion between peo­ple and technology.

“We are delighted with the strong back­ing from our exist­ing Euro­pean investor base and the new investors who have come on board in this round. With the A2 round, we are ide­ally posi­tioned for the next steps on the road to an arti­fi­cial voice for voice­less people.”

Rudolf von Bünau, Man­ag­ing Direc­tor and co-founder, Altavo GmbH

“Altavo’s devel­op­men­tal and clin­i­cal progress and its expe­ri­enced man­age­ment team con­vinced us to also par­tic­i­pate in the A2 round — together with bm|t in the role of co-lead investor.”

Jaroslav Belot­serkovsky, Invest­ment Man­ager, Novalis Biotech

“Altavo remains a prime exam­ple of the trans­la­tion of uni­ver­sity research into start-up com­pa­nies and of suc­cess­ful fund­ing pol­icy in Cen­tral Ger­many, beyond the bor­ders of the fed­eral state. We are delighted to be able to sup­port the expe­ri­enced Altavo team in real­iz­ing its ambi­tious vision.” 

Michael Thiele, Invest­ment Man­ager, bm |t beteili­gungs­man­age­ment thürin­gen gmbh and Sören Schus­ter, Man­ag­ing Direc­tor, TGFS Tech­nolo­giegrün­der­fonds Sachsen

About Altavo

Altavo GmbH is a med­ical tech­nol­ogy start-up founded in Feb­ru­ary 2021 and based in Dres­den. Based on non-inva­sive radar sen­sor tech­nol­ogy and arti­fi­cial intel­li­gence, Altavo devel­ops pros­thet­ics to improve the reha­bil­i­ta­tion of voice­less and vocally impaired patients. At its loca­tions in Dres­den and Jena, Altavo cur­rently employs 16 peo­ple with many years of expe­ri­ence in the fields of AI / data sci­ence, speech tech­nol­ogy, high-fre­quency tech­nol­ogy, med­ical tech­nol­ogy and voice therapy.

Altavo coop­er­ates with the Chair of Lan­guage Tech­nol­ogy and Cog­ni­tive Sys­tems and the Chair of High Fre­quency Tech­nol­ogy at the Tech­ni­cal Uni­ver­sity of Dres­den. The col­lab­o­ra­tion is funded by the Free State of Sax­ony and co-financed by the Euro­pean Union as part of the SEMECO Future Clus­ter in the “B3 / MUSIK” project.

Press con­tact: Rudolf v. Bünau, rudolf.vonbuenau@altavo.eu

About Novalis Biotech

Novalis Biotech (Ghent, Bel­gium) is an early-stage ven­ture cap­i­tal investor that invests in tech­nolo­gies that are rev­o­lu­tion­iz­ing health­care. The com­pa­ny’s core com­pe­tence lies in the dig­i­tal­iza­tion of life sci­ences, with a focus on bioin­for­mat­ics, genomics and diag­nos­tics. Novalis believes in the appli­ca­tion of inno­v­a­tive tech­nolo­gies to advance the pre­ven­tion, diag­no­sis or treat­ment of diseases.

For more infor­ma­tion, please visit www.noval.is

About bm | t beteiligungsmanagement thüringen

bm | t, based in Erfurt, is the lead­ing address for ven­ture cap­i­tal invest­ments in Thuringia. bm | t cur­rently man­ages 13 funds with a total vol­ume of around EUR 465 mil­lion, which invest in inno­v­a­tive com­pa­nies in almost all sec­tors and in all phases of com­pany devel­op­ment — both in the start-up and growth phases or in com­pany suc­ces­sion situations.

Fur­ther infor­ma­tion can be found at www.bm‑t.de

Press con­tact: Michael Thiele, michael.thiele@bm‑t.de

About the TGFS Technologiegründerfonds Sachsen

TGFS is an equity investor for knowl­edge-based, tech­nol­ogy-ori­ented start-ups in Sax­ony. It is the lead­ing start-up financier in the Free State of Sax­ony and sup­ports teams with ven­ture cap­i­tal and man­age­ment sup­port in both the seed and start-up phases. An invest­ment by TGFS gives port­fo­lio com­pa­nies access to other inter­na­tional investors.

The fund was first launched in 2008 by the Free State of Sax­ony (with ERDF fund­ing, among other things) and Saxon finan­cial insti­tu­tions and has since sup­ported over 100 start-ups in what is now the third gen­er­a­tion of the fund.

Press con­tact: Sören Schus­ter, Phone +49 172 2001097, soeren.schuster@cfh.de

About the HTGF — High-Tech Gründerfonds

HTGF is one of the lead­ing and most active early-stage investors in Ger­many and Europe, financ­ing start-ups in the fields of deep tech, indus­trial tech, cli­mate tech, dig­i­tal tech, life sci­ences and chem­i­cals. With its expe­ri­enced invest­ment team, HTGF sup­ports star­tups in all phases of their devel­op­ment into inter­na­tional mar­ket lead­ers. HTGF invests in the pre-seed and seed phase and can make sig­nif­i­cant invest­ments in fur­ther financ­ing rounds. Since its foun­da­tion in 2005, it has financed around 800 start-ups and real­ized 200 suc­cess­ful exits. HTGF has a fund vol­ume of over 2 bil­lion euros.

Fund investors in the pub­lic-pri­vate part­ner­ship include the Ger­man Fed­eral Min­istry for Eco­nomic Affairs and Energy, KfW Cap­i­tal and 45 com­pa­nies and fam­ily offices.

Fur­ther infor­ma­tion can be found at www.HTGF.de.

Press con­tact: Tobias Jacob, Senior Mar­ket­ing & Com­mu­ni­ca­tions Man­ager, Phone +49 228 82300 121, t.jacob@htgf.de

About Ostwerk

Ost­werk GmbH is a wholly owned sub­sidiary of Sparda-Bank Berlin eG, an invest­ment com­pany founded in 2024 and based in Berlin. As a part­ner­ship investor, the com­pany invests equity in young com­pa­nies that want to ful­fill their regional respon­si­bil­ity in a sus­tain­able man­ner and thus cre­ate future prospects in east­ern Ger­many. The com­pany com­bines finan­cial invest­ment with strate­gic sup­port and a value- and net­work-based approach to enable long-term eco­nomic and social devel­op­ment. Ost­werk is active in all six east­ern Ger­man states and is aimed specif­i­cally at young com­pa­nies with regional and social aspirations.

Press con­tact: Johannes Ulrich and Franz Neu­mann (Man­ag­ing Direc­tors), hallo@ost-werk.de, www.ost-werk.de